(1R)-(1S,2S,3R,5S)-P二醇-N-(N-吡嗪基苯基丙氨酰基)-1-氨基-3-甲基丁烷-1-硼酸酯结构式
|
常用名 | (1R)-(1S,2S,3R,5S)-P二醇-N-(N-吡嗪基苯基丙氨酰基)-1-氨基-3-甲基丁烷-1-硼酸酯 | 英文名 | BORTEZOMIB-PINANEDIOL |
---|---|---|---|---|
CAS号 | 205393-22-2 | 分子量 | 518.455 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 719.5±60.0 °C at 760 mmHg | |
分子式 | C29H39BN4O4 | 熔点 | 75-83ºC | |
MSDS | N/A | 闪点 | 389.0±32.9 °C |
用途Bortezomib-pinanediol is a prodrug of Bortezomib, as well as a proteasome inhibitor. |
中文名 | 保特佐米蒎烷二醇酯 |
---|---|
英文名 | bortezomib-pinanediol |
英文别名 | 更多 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 719.5±60.0 °C at 760 mmHg |
熔点 | 75-83ºC |
分子式 | C29H39BN4O4 |
分子量 | 518.455 |
闪点 | 389.0±32.9 °C |
精确质量 | 518.306458 |
PSA | 102.44000 |
LogP | 4.81780 |
外观性状 | 黄色固体 |
蒸汽压 | 0.0±2.3 mmHg at 25°C |
折射率 | 1.572 |
储存条件 | -20°C,保存于惰性气体中 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4365 - 4377 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4365 - 4377 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4365 - 4377 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4365 - 4377 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4365 - 4377 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4365 - 4377 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:WO2012/48745 A1, ; |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Bioorganic and Medicinal Chemistry, , vol. 21, # 4 p. 1018 - 1029 |
~% (1R)-(1S,2S,3R,... 205393-22-2 |
文献:Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4365 - 4377 |
Bortezomib pinanediol ester |
2-Pyrazinecarboxamide, N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]- |
N-{(1R)-3-Methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0]dec-4-yl]butyl}-Nα-(2-pyrazinylcarbonyl)-L-phenylalaninamide |
Bortezomib intermediates III |